News Category
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to execute a Phase 2 trial of Lucid...
India's drug regulator has cleared Okogen's Phase 1/2 EMERALD study of Treyegen, a single therapy targeting both viral and bacterial conjunctivitis, p...
Helus Pharma Inc. has officially changed its legal name from Cybin Inc., a move that reflects its evolution from a clinical-stage discovery company to...
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) subsidiary MindWave Innovations Inc. has signed a 12-month technology services agreement with S...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, which could significantly improv...
American Fusion Inc. has advanced its Texatron fusion program into active testing, achieving peak confinement pressures of 100,000 atmospheres, a key ...
The two-day conference organized by Moody Capital Solutions aims to connect investors with emerging and under-covered companies in the disruptive grow...
SuzieQ Holdings' participation in the Moody Capital Solutions conference underscores the growing importance of quantum-safe cryptography and the capit...
A new study confirms that treating selected ER patients while seated, rather than waiting for a bed, speeds up care and reduces wait times, potentiall...
Helus Pharma's Phase 3 program for HLP003 in major depressive disorder is progressing with enrollment completed and topline data expected in Q4 2026, ...
Helus Pharma's appointment of Michael Halstead as CEO signals strategic preparation for commercialization as its lead candidate HLP003 advances throug...
Ocumetics Technology Corp. has completed the second tranche of its private placement, raising $2.5 million to fund its first-in-human clinical trials ...
VERAXA Biotech AG shareholders approved key governance and financing measures with over 99.94% support, enabling strategic flexibility for growth.
VERAXA Biotech announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, moving the p...
Gerresheimer has started operations at a new state-of-the-art plant in Zhenjiang Dagang, China, doubling its production capacity for glass primary pac...
Darwin AG has changed its name to Novogenia AG, aligning the parent company with its core operating brand to enhance market visibility and support int...
NanoViricides reports progress toward a Phase II trial of its oral gummies formulation NV-387 for the Bundibugyo ebolavirus outbreak in the DRC, which...
Redwood AI Corp. has been added to the CSE25 Index, highlighting its position among the largest companies on the Canadian Securities Exchange and pote...
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trials for HLP003 in major depressive disorder, with topline data exp...
Quantum BioPharma Ltd. is featured in a BioMedWire editorial highlighting the limitations of current MS therapies and the potential of its drug candid...
The article highlights how advanced drug delivery systems, such as Oncotelic Therapeutics' Deciparticle platform, are gaining traction as a cost-effec...
Quantum BioPharma is progressing its novel MS therapy Lucid-MS to Phase 2 trials after positive Phase 1 results, offering a potential shift from immun...
VERAXA Biotech's new in vitro data validates its BiTAC-ADC platform's ability to selectively kill cancer cells while minimizing toxicity, supporting i...
Redwood AI Corp. uses proprietary AI platforms to accelerate chemistry research and development, with implications for faster drug discovery, defense ...
NanoViricides announced approval from the DRC Pillar Committee to proceed with a Phase II trial of NV-387 Oral Gummies for the Bundibugyo ebolavirus o...
Helus Pharma announced that its Chief Medical Officer will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid ...
Onco-Innovations has initiated process development and scale-up activities for its proprietary drug candidate ONC010, a key step toward IND-enabling s...
Quantum BioPharma's LUCID-MS program shows promise in addressing myelin repair and neuroprotection for MS, with a favorable safety profile in phase 1 ...
NeuroOne Medical Technologies will present at the Planet MicroCap Las Vegas 2026 Conference on June 17, 2026, providing commercialization updates and ...
GeoVax CEO comments on recent pharmaceutical industry acquisitions that signal a strategic shift toward prioritizing vaccine innovation, health securi...
Quantum BioPharma advances its lead MS drug candidate Lucid-MS and commercial alcohol metabolism product unbuzzd(TM), with an upcoming Phase 2 trial a...
Helus Pharma announced its participation in a fireside chat at the Jefferies Global Healthcare Conference, highlighting its Phase 3 and Phase 2 trials...
TransCode Therapeutics has started a Phase 2a trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduce recurre...
NanoViricides announces that its broad-spectrum antiviral candidate NV-387 should be evaluated for treating the Bundibugyo strain Ebola outbreak, give...
SureNano Science Ltd. is positioning itself in the booming GLP-1 therapy market by advancing GEP-44, a patented peptide with potential for improved to...
Oncotelic Therapeutics integrates 28 million scientific abstracts into its proprietary PDAOAI platform, positioning itself as a key player in the rapi...
Telomir Pharmaceuticals announced the publication of peer-reviewed preclinical data showing that Telomir-Zn improves survival and reduces oxidative st...
Lantern Pharma announced FDA clearance on proposed protocol amendments for its Phase 2 HARMONIC trial, clarifying a regulatory path focusing on EGFR e...
NanoViricides emphasizes the potential of its oral drug candidate NV-387 as a pandemic preparedness tool against the current Ebola outbreak, targeting...
Quantum BioPharma reports that patient enrollment in its collaborative MS imaging study with Massachusetts General Hospital has reached the halfway po...
LIXTE Biotechnology advances its oncology pipeline with LB-100 ovarian cancer trial expansion and growth at its Liora Technologies subsidiary, signali...
Dogwood Therapeutics announced first quarter 2026 financial results, highlighting strong operational start with significant pipeline progress for Haln...
Innovations in crossing the blood-brain barrier, such as Oncotelic's intranasal nose-to-brain system, are poised to transform CNS drug delivery and op...
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related neuropsychiatric conditions...
A hantavirus outbreak on the MV Hondius cruise ship has resulted in three fatalities, highlighting the dangers of this rare infection and the importan...
NanoViricides' broad-spectrum antiviral NV-387 has been granted Orphan Drug Designation by the FDA for measles, offering regulatory incentives and pos...
VolitionRx announced a technical milestone in detecting nucleosomes in capillary blood from sepsis patients using a lateral flow finger-prick prototyp...
Helus Pharma collaborates with TARA Mind and VETS to enhance veteran recruitment for its Phase 3 trial of HLP003 for major depressive disorder, levera...
